Manulife Financial

L'entreprise

Manulife is one of Canada's largest life insurers, operating in Canada, the U.S. (John Hancock) and — its key growth engine — Asia, plus Global Wealth & Asset Management (Manulife Investment Management).

It has de-risked its legacy long-term-care and legacy blocks through reinsurance, freeing capital for buybacks and dividends.

Les avantages concurrentiels

Scale, a strong Asian franchise and a capital-light wealth/asset-management business that compounds fee income.

Diversification across geographies and products smooths results.

Aperçu financier

Période déclarée la plus récente : Q1 FY2026 (ended March 31, 2026). Les chiffres reflètent la date de révision — confirmez les chiffres actuels avant d'agir.

Rendement du flux de trésorerie disponible et croissance durable

Rendement des bénéfices : ≈6.1%≈ earnings yield (trailing P/E ~16.4)

Free cash flow isn't a meaningful metric for a life insurer — Manulife is judged on core ROE, core-EPS growth, book value and regulatory capital (LICAT).

The engine here is a rising core ROE (16.5%, targeting 18%+ by 2027) and a very strong LICAT ratio of 136% — roughly C$25B above the supervisory target — which funds ongoing buybacks and dividend increases.

Sustainable growth: Asia new-business growth plus Global WAM fee income support mid-to-high-single-digit core-EPS growth, amplified per share by buybacks.

Voir le classement complet du rendement des bénéfices →

Valorisation et points à surveiller

Life insurers are valued on core earnings, ROE and book value — not free cash flow. Manulife trades at a modest multiple with a solid dividend yield, reflecting its Asia leverage and improving returns.

The re-rating case is core ROE reaching the 18%+ target while capital keeps being returned.

Dividende

Pays a C$0.485 quarterly dividend after a ~10% hike in 2025; a 136% LICAT ratio and legacy de-risking underpin continued increases and buybacks.

Risques et scénario baissier

• Sensitivity to interest rates and equity markets (which drive both results and fee income).
• Asia macro and currency exposure.
• Legacy long-term-care blocks, though materially de-risked via reinsurance.
• Reported earnings can swing far from core earnings on market movements.

Faits récents

Q1 FY2026 core earnings of C$1.84B and core EPS of C$1.06 (+11%), with core ROE at 16.5% and LICAT at 136%; management reiterated an 18%+ core-ROE target by 2027.

Verdict

An improving-ROE, capital-return life insurer with real Asia and asset-management growth. The bull case is the ROE march to 18%+ plus buybacks; the bear case is market/rate sensitivity and Asia macro. Conviction: a reasonably-valued compounder-plus-income name for patient investors.